Parkman Healthcare Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.91M	Sell	26,916 -20,787	-44%	-$7.07M	0.92%	40
2025 Q4	$19M	Sell	47,703 -39,987	-46%	-$17.7M	1.81%	19
2025 Q3	$40M	Sell	87,690 -4,648	-5%	-$1.89M	4.39%	3
2025 Q2	$30.1M	Buy	92,338 +23,400	+34%	+$6.47M	3.48%	4
2025 Q1	$18.6M	Buy	68,938 +30,266	+78%	+$7.78M	2.21%	14
2024 Q4	$9.1M	Buy	38,672 +13,187	+52%	+$3.47M	1.21%	32
2024 Q3	$7.01M	Buy	+25,485	New	+$6.64M	0.89%	42
2022 Q4	–	Sell	-10,873	Closed	-$2.18M	–	82
2022 Q3	$2.18M	Sell	10,873 -9,861	-48%	-$1.88M	0.62%	53
2022 Q2	$3.02M	Sell	20,734 -33,274	-62%	-$4.72M	1.11%	32
2022 Q1	$8.82M	Sell	54,008 -3,674	-6%	-$560K	2.58%	12
2021 Q4	$9.78M	Sell	57,682 -17,285	-23%	-$3.21M	2.21%	17
2021 Q3	$14.2M	Hold	74,967	–	–	3.58%	6
2021 Q2	$12.7M	Buy	74,967 +9,924	+15%	+$1.45M	2.78%	10
2021 Q1	$9.18M	Buy	65,043 +28,882	+80%	+$4.35M	2.21%	13
2020 Q4	$4.7M	Buy	36,161 +5,298	+17%	+$707K	1.2%	32
2020 Q3	$4.49M	Sell	30,863 -5,000	-14%	-$711K	1.19%	37
2020 Q2	$5.31M	Sell	35,863 -500	-1%	-$67.4K	1.53%	29
2020 Q1	$3.96M	Buy	36,363 +1,363	+4%	+$157K	1.83%	21
2019 Q4	$4.03M	Buy	+35,000	New	+$3.49M	1.19%	30